

Adriano Piris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7699105/publications.pdf>

Version: 2024-02-01

18
papers

1,075
citations

759233

12
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

2596
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
2	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 643-654.	3.4	226
3	Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. <i>Genome Medicine</i> , 2020, 12, 30.	8.2	71
4	BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. <i>Human Pathology</i> , 2015, 46, 239-245.	2.0	62
5	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	6.4	55
6	AJCC melanoma staging update: impact on dermatopathology practice and patient management. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 394-400.	1.3	48
7	Cutaneous and mammary apocrine carcinomas have different immunoprofiles. <i>Human Pathology</i> , 2014, 45, 320-326.	2.0	47
8	p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. <i>Human Pathology</i> , 2014, 45, 1078-1083.	2.0	35
9	Loss of BAP1 Expression in Basal Cell Carcinomas in Patients With Germline BAP1 Mutations. <i>American Journal of Clinical Pathology</i> , 2015, 143, 901-904.	0.7	25
10	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	4.6	25
11	Progress in Melanoma Histopathology and Diagnosis. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 467-480.	2.2	24
12	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 491-499.e2.	1.2	14
13	Epidermal Growth Factor Receptor Gene Status by Fluorescence In Situ Hybridization in Malignant, Atypical, and Benign Hidradenomas. <i>American Journal of Dermatopathology</i> , 2010, 32, 586-592.	0.6	11
14	Melanoma Staging. <i>Dermatologic Clinics</i> , 2012, 30, 581-592.	1.7	11
15	Continuous Spatial Sequences of Lichen Sclerosus, Penile Intraepithelial Neoplasia, and Invasive Carcinomas: A Study of 109 Cases. <i>International Journal of Surgical Pathology</i> , 2019, 27, 477-482.	0.8	10
16	Lethal melanoma in children: a clinicopathological study of 12 cases. <i>Pathology</i> , 2016, 48, 705-711.	0.6	8
17	Mechanisms of Metastasis: Seed and Soil. <i>Cancer Treatment and Research</i> , 2007, 135, 119-127.	0.5	8
18	Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, e70-e72.	1.6	3